Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tommaso Matucci, Luisa Galli, Maurizio de Martino & Elena Chiappini. (2019) Treating children with tuberculosis: new weapons for an old enemy. Journal of Chemotherapy 31:5, pages 227-245.
Read now
Read now
Yi-Hsing Chen, Hellen MDS de Carvalho, Umut Kalyoncu, Lyndon John Q Llamado, Gaston Solano, Ron Pedersen, Galina Lukina, Juan J Lichauco & Radu S Vasilescu. (2018) Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics: Targets and Therapy 12, pages 1-9.
Read now
Read now
Dhiren Patel, Shailender Madani, Shraddha Patel & Lokesh Guglani. (2016) Review of pulmonary adverse effects of infliximab therapy in Crohn’s disease. Expert Opinion on Drug Safety 15:6, pages 769-775.
Read now
Read now
Bincy P Abraham. (2015) Symptom management in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 9:7, pages 953-967.
Read now
Read now
Articles from other publishers (36)
John H. Kempen, Craig W. Newcomb, Terri L. Washington, C. Stephen Foster, Lucia Sobrin, Jennifer E. Thorne, Douglas A. Jabs, Eric B. Suhler, James T. Rosenbaum, H. Nida Sen, Grace A. Levy-Clarke, Robert B. Nussenblatt, Nirali P. Bhatt, Careen Y. Lowder, Debra A. Goldstein, Yannek I. Leiderman, Nisha R. Acharya, Gary N. Holland, Russell W. Read, James P. Dunn, Kurt A. Dreger, Pichaporn Artornsombudh, Hosne A. Begum, Tonetta D. Fitzgerald, Srishti Kothari, Abhishek R. Payal, Ebenezer Daniel, Sapna S. Gangaputra, R. Oktay Kaçmaz, Teresa L. Liesegang, Siddharth S. Pujari, Naira Khachatryan, Armin Maghsoudlou, Hilkiah K. Suga, Clara M. Pak, Kathy J. Helzlsouer & Jeanine M. Buchanich. (2023) Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality. Ophthalmology 130:12, pages 1258-1268.
Crossref
Crossref
Sean L. Lapp, Meenakshi Bewtra, James D. Lewis, Manreet Kaur, Themistocles Dassopoulos, Scott B. Snapper, Joshua R. Korzenik, Matthew Bohm, Laura Raffals, Beniwal-Patel Poonam, David Hudesman, Kirk Russ, Loren Brook, Joel Pekow, Raymond Cross, Uni Wong, Shrinivas Bishu, Meenakshi Bewtra, James D. Lewis, Richard Duerr, Sumona Saha, Freddy Caldera, Elizabeth Scoville, Parakkal Deepak & Matthew Ciorba. (2023) Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough. Clinical Gastroenterology and Hepatology.
Crossref
Crossref
Nina Jahnich & Peter D. Arkwright. (2023) Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review. Frontiers in Pharmacology 14.
Crossref
Crossref
Florian Schmid, Cho-Ming Chao & Jan Däbritz. (2022) Pathophysiological Concepts and Management of Pulmonary Manifestation of Pediatric Inflammatory Bowel Disease. International Journal of Molecular Sciences 23:13, pages 7287.
Crossref
Crossref
Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem & Amirhossein Nafari. (2022) The Risk of Opportunistic Infections in Patients with Inflammatory
Bowel Disease. The International Journal of Gastroenterology and Hepatology Diseases 1:1.
Crossref
Crossref
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo & Sang Hyoung Park. (2021) Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea. BMC Gastroenterology 21:1.
Crossref
Crossref
Kyuwon Kim, Kyung-Wook Jo, Tae Sun Shim, Jin Hwa Park, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang & Byong Duk Ye. (2021) Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors. Frontiers in Medicine 8.
Crossref
Crossref
Tae-Jong Kim. (2021) Biologic therapies for the treatment of psoriatic arthritis. Journal of the Korean Medical Association 64:2, pages 124-129.
Crossref
Crossref
Lingna Ye, Thomas P. Chapman, Zhenzhen Wen, Lang Lin, Yun Qiu, Zhanju Liu, Zhihua Ran, Jiaming Qian, Kaichun Wu, Xiang Gao, Pinjin Hu, Minhu Chen, Simon P. L. Travis & Qian Cao. (2020) Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region. Alimentary Pharmacology & Therapeutics 53:3, pages 390-399.
Crossref
Crossref
Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei & Shashi Adsul. (2020) Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut and Liver 14:6, pages 685-698.
Crossref
Crossref
Natália S.F. Queiroz & Miguel Regueiro. (2020) Safety considerations with biologics and new inflammatory bowel disease therapies. Current Opinion in Gastroenterology 36:4, pages 257-264.
Crossref
Crossref
Virginia E Duncan, Karen M Chisholm & M Cristina Pacheco. (2019) Effects of Tumor Necrosis Factor Alpha Inhibitors on Lymph Node and Ileocecal Mucosa-Associated Lymphoid Tissue Architecture in Patients With Inflammatory Bowel Disease. Pediatric and Developmental Pathology 23:2, pages 115-120.
Crossref
Crossref
Jihye Kim, Jaeyoung Chun, Changhyun Lee, Kyungdo Han, Seungho Choi, Jooyoung Lee, Hosim Soh, Kookhwan Choi, Seona Park, Eun Ae Kang, Hyun Jung Lee, Jong Pil Im & Joo Sung Kim. (2019) Increased risk of idiopathic pulmonary fibrosis in inflammatory bowel disease: A nationwide study. Journal of Gastroenterology and Hepatology 35:2, pages 249-255.
Crossref
Crossref
Jihye KimJong Pil Im, Jae-Joon YimChang Kyun LeeDong Il ParkChang Soo EunSung-Ae JungJeong Eun ShinKang-Moon LeeJae Hee Cheon. (2020) Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy. The Korean Journal of Gastroenterology 75:1, pages 29.
Crossref
Crossref
Yunho Jung. (2020) Anti-tumor Necrosis Factor Agents and Tuberculosis in Inflammatory Bowel Disease. The Korean Journal of Gastroenterology 75:1, pages 1.
Crossref
Crossref
Philippe Camus & Thomas V. Colby. 2019. Pulmonary Manifestations of Systemic Diseases. Pulmonary Manifestations of Systemic Diseases
228
261
.
Christopher Andrew Lamb, Nicholas A Kennedy, Tim Raine, Philip Anthony Hendy, Philip J Smith, Jimmy K Limdi, Bu’Hussain Hayee, Miranda C E Lomer, Gareth C Parkes, Christian Selinger, Kevin J Barrett, R Justin Davies, Cathy Bennett, Stuart Gittens, Malcolm G Dunlop, Omar Faiz, Aileen Fraser, Vikki Garrick, Paul D Johnston, Miles Parkes, Jeremy Sanderson, Helen Terry, Daniel R Gaya, Tariq H Iqbal, Stuart A Taylor, Melissa Smith, Matthew Brookes, Richard Hansen & A Barney Hawthorne. (2019) British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68:Suppl 3, pages s1-s106.
Crossref
Crossref
J C Silva, A Rodrigues & J Carvalho. (2019) Spontaneous Resolution of Enterocutaneous Fistula After Disseminated Tuberculosis Treatment in a Patient With Crohn’s Disease: Challenges in Biologic Therapy. Inflammatory Bowel Diseases.
Crossref
Crossref
Xing Wang, Sunny H Wong, Xian-Song Wang, Whitney Tang, Chang-Qin Liu, Gani Niamul, Bin Wu, Lai-Shan Tam, Justin C Y Wu, Francis K L Chan, Joseph J Y Sung & Siew C Ng. (2019) Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region. Rheumatology 58:5, pages 803-810.
Crossref
Crossref
Yu Kyung JunJaeyoung Chun, Eun Ae KangHyun Jung LeeJong Pil ImJoo Sung Kim. (2019) Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. The Korean Journal of Gastroenterology 74:3, pages 168.
Crossref
Crossref
Serena R. Martin & Robert V. Bryant. 2019. Inflammatory Bowel Disease Nursing Manual. Inflammatory Bowel Disease Nursing Manual
189
204
.
Jihye Park & Jae Hee Cheon. (2018) Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease. Gut and Liver 12:6, pages 623-632.
Crossref
Crossref
Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia & Vineet Ahuja. (2018) High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intestinal Research 16:4, pages 588-598.
Crossref
Crossref
Guilherme P Ramos, Gregory Stroh, Badr Al-Bawardy, William A Faubion, Konstantinos A Papadakis & Patricio Escalante. (2018) Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 24:10, pages 2272-2277.
Crossref
Crossref
Dong Il ParkTadakazu HisamatsuMinhu ChenSiew Chien NgChoon Jin OoiShu Chen WeiRupa BanerjeeIda Normiha HilmiYoon Tae JeenDong Soo HanHyo Jong KimZhihua RanKaichun WuJiaming QianPin-Jin HuKatsuyoshi MatsuokaAkira AndohYasuo SuzukiKentaro SuganoMamoru WatanabeToshifumi HibiAmarender S. PuriSuk-Kyun Yang. (2018) Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intestinal Research 16:1, pages 4.
Crossref
Crossref
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri & Suk-Kyun Yang. (2018) Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. Journal of Gastroenterology and Hepatology 33:1, pages 20-29.
Crossref
Crossref
Renée M. Marchioni Beery & Joshua R. Korzenik. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
185
211
.
Eun Hye Lee, Young Ae Kang, Ah Young Leem, Moo Suk Park, Young Sam Kim, Se Kyu Kim, Joon Chang & Song Yee Kim. (2017) Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. Scientific Reports 7:1.
Crossref
Crossref
Jungsil Lee, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee, Eun Young Lee, Jong Pil Im, Sung Koo Han & Jae-Joon Yim. (2017) Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. Annals of the American Thoracic Society 14:5, pages 690-697.
Crossref
Crossref
Jae Hee Cheon. (2017) Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 32:4, pages 769-777.
Crossref
Crossref
Eric D. Shah, Jeremy P. Farida, Corey A. Siegel, Kelly Chong & Gil Y. Melmed. (2017) Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD. Inflammatory Bowel Diseases 23:4, pages 570-577.
Crossref
Crossref
Elizabeth S. John, Kristina Katz, Mark Saxena, Sita Chokhavatia & Seymour Katz. (2016) Management of Inflammatory Bowel Disease in the Elderly. Current Treatment Options in Gastroenterology 14:3, pages 285-304.
Crossref
Crossref
Jatinderpal SinghAmarender S PuriSanjeev SachdevaPuja SakhujaKulandaivelu Arivarasan. (2016) Rectal tuberculosis after infliximab therapy despite negative screening for latent tuberculosis in a patient with ulcerative colitis. Intestinal Research 14:2, pages 183.
Crossref
Crossref
Jang Wook LeeChang Hwan ChoiJi Hoon ParkJeong Wook KimSang Bum KangJa Seol KooYoung-Ho KimYou Sun KimYoung Eun JooSae Kyung Chang. (2016) Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intestinal Research 14:2, pages 146.
Crossref
Crossref
Paula Sousa & Matthieu Allez. (2015) Complications of biologics in inflammatory bowel disease. Current Opinion in Gastroenterology 31:4, pages 296-302.
Crossref
Crossref
Jung Won LeeJong Pil ImJae Hee CheonYou Sun Kim, Joo Sung KimDong Soo Han. (2015) Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future. Intestinal Research 13:3, pages 213.
Crossref
Crossref